SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 49.30-2.8%Nov 20 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (23350)3/29/2007 3:09:36 PM
From: zeta1961  Read Replies (1) of 52153
 
Right now, clinician panel members are discussing how the small numbers(80 in treatment arm, 40 in control of 9901 which did show stat sig O.01 at 3 years) and make them uncomfortable to provide this to their patients..that Taxotere studies were in a sicker population(2.4month advantage) and therefore should not be compared..and that there's no rush to approve since the FDA does have Expanded Access programs so that patients who want this therapy can get it before it's approved

Edit: they went on to ask detailed Q's for ongoing P3..DNDN said they've accrued 400 of 500 target..primary endpoint: OS, secondary: TTP
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News